Numerai GP LLC Cuts Stock Position in Bruker Co. (NASDAQ:BRKR)

Numerai GP LLC cut its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 21.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,129 shares of the medical research company's stock after selling 6,751 shares during the quarter. Numerai GP LLC's holdings in Bruker were worth $1,414,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. London Co. of Virginia increased its position in shares of Bruker by 78.4% during the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Brown Advisory Inc. increased its holdings in Bruker by 10.1% in the 4th quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company's stock worth $118,806,000 after buying an additional 185,912 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Bruker by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after purchasing an additional 20,273 shares during the period. FIL Ltd boosted its stake in Bruker by 262.3% in the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after purchasing an additional 1,420,102 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Bruker by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,687,364 shares of the medical research company's stock valued at $98,914,000 after acquiring an additional 313,171 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Trading Up 0.0%

Shares of NASDAQ:BRKR traded up $0.01 during mid-day trading on Monday, reaching $37.54. The stock had a trading volume of 395,653 shares, compared to its average volume of 1,599,745. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The firm has a 50 day simple moving average of $40.33 and a two-hundred day simple moving average of $50.41. The firm has a market cap of $5.69 billion, a PE ratio of 49.42, a price-to-earnings-growth ratio of 2.16 and a beta of 1.23. Bruker Co. has a twelve month low of $34.10 and a twelve month high of $78.94.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The business had revenue of $801.40 million during the quarter, compared to analyst estimates of $763.83 million. During the same period in the prior year, the firm posted $0.53 EPS. Bruker's quarterly revenue was up 11.0% compared to the same quarter last year. On average, research analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Monday, June 16th will be given a $0.05 dividend. The ex-dividend date is Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.53%. Bruker's dividend payout ratio is currently 38.46%.

Analysts Set New Price Targets

Several equities analysts have issued reports on BRKR shares. Citigroup cut their target price on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. UBS Group reduced their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. The Goldman Sachs Group decreased their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Guggenheim reissued a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Barclays cut their price objective on shares of Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.10.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.